Importantly, KRAS has been shown to not possess oncogenic functions in pancreatic endocrine cells and activating KRAS mutations were never found in islet cell tumors (Supplementary Fig. 3c, d)21,37. This evidence concerns the gene KRAS and pancreatic neuroendocrine tumor.